View in EDS

Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer

Saved in:
Bibliographic Details
Title: Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer
Authors: Hatzipanagiotou, Maria Eleni, Pigerl, Miriam, Gerken, Michael, Räpple, Sophie, Zeltner, Verena, Hetterich, Madeleine, Ugocsai, Peter, Inwald, Elisabeth Christine, Klinkhammer-Schalke, Monika, Ortmann, Olaf, Seitz, Stephan
Source: Breast Cancer Res Treat
Publisher Information: Springer Science and Business Media LLC, 2024.
Publication Year: 2024
Subject Terms: 0301 basic medicine, ddc:610, Epidemiology, 610 Medizin, Triple Negative Breast Neoplasms, Breast Neoplasms, Combined Modality Therapy, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Chemotherapy, Adjuvant, Triple negative breast cancer · Timing of adjuvant chemotherapy · Population-based cancer registry · Outcomes in TNBC · Routine practice data, Humans, Female, Female [MeSH], Timing of adjuvant chemotherapy, Triple Negative Breast Neoplasms/pathology [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Neoplasm Staging [MeSH], Triple negative breast cancer, Population-based cancer registry, Chemotherapy, Adjuvant/methods [MeSH], Outcomes in TNBC, Routine practice data, Combined Modality Therapy [MeSH], Breast Neoplasms/pathology [MeSH], Retrospective Studies, Neoplasm Staging
Description: Purpose The optimal time to initiation of adjuvant chemotherapy (TTAC) for triple negative breast cancer (TNBC) patients is unclear. This study evaluates the association between TTAC and survival in TNBC patients. Methods We conducted a retrospective study using data from a cohort of TNBC patients diagnosed between January 1, 2010 to December 31, 2018, registered in the Tumor Centre Regensburg was conducted. Data included demographics, pathology, treatment, recurrence and survival. TTAC was defined as days from primary surgery to first dose of adjuvant chemotherapy. The Kaplan–Meier method was used to evaluate impact of TTAC on overall survival (OS) and 5-year OS. Results A total of 245 TNBC patients treated with adjuvant chemotherapy and valid TTAC data were included. Median TTAC was 29 days. The group receiving systemic therapy within 22 to 28 days after surgery had the most favorable outcome, with median OS of 10.2 years. Groups receiving systemic therapy between 29–35 days, 36–42 days, and more than 6 weeks after surgery had significantly decreased median survival, with median OS of 8.3 years, 7.8 years, and 6.9 years, respectively. Patients receiving therapy between 22–28 days had significantly better survival compared to those receiving therapy between 29–35 days (p = 0.043), and patients receiving therapy after 22–28 days also demonstrated significantly better survival compared to those receiving therapy after more than 43 days (p = 0.033). Conclusion Timing of adjuvant systemic therapy can influence OS in TNBC patients. Efforts should be made to avoid unnecessary delays in administering chemotherapy to ensure timely initiation of systemic therapy and optimize patient outcomes.
Document Type: Article
Other literature type
File Description: application/pdf
Language: English
ISSN: 1573-7217
0167-6806
DOI: 10.1007/s10549-023-07207-4
DOI: 10.5283/epub.55406
DOI: 10.5283/epub.5540610.1007/s10549-023-07207-4
Access URL: https://pubmed.ncbi.nlm.nih.gov/38238552
https://repository.publisso.de/resource/frl:6522803
https://epub.uni-regensburg.de/55406/
Rights: CC BY
Accession Number: edsair.doi.dedup.....1a053c0183fc1ac0d1c0f6d73b7429fe
Database: OpenAIRE
Description
Abstract:Purpose The optimal time to initiation of adjuvant chemotherapy (TTAC) for triple negative breast cancer (TNBC) patients is unclear. This study evaluates the association between TTAC and survival in TNBC patients. Methods We conducted a retrospective study using data from a cohort of TNBC patients diagnosed between January 1, 2010 to December 31, 2018, registered in the Tumor Centre Regensburg was conducted. Data included demographics, pathology, treatment, recurrence and survival. TTAC was defined as days from primary surgery to first dose of adjuvant chemotherapy. The Kaplan–Meier method was used to evaluate impact of TTAC on overall survival (OS) and 5-year OS. Results A total of 245 TNBC patients treated with adjuvant chemotherapy and valid TTAC data were included. Median TTAC was 29 days. The group receiving systemic therapy within 22 to 28 days after surgery had the most favorable outcome, with median OS of 10.2 years. Groups receiving systemic therapy between 29–35 days, 36–42 days, and more than 6 weeks after surgery had significantly decreased median survival, with median OS of 8.3 years, 7.8 years, and 6.9 years, respectively. Patients receiving therapy between 22–28 days had significantly better survival compared to those receiving therapy between 29–35 days (p = 0.043), and patients receiving therapy after 22–28 days also demonstrated significantly better survival compared to those receiving therapy after more than 43 days (p = 0.033). Conclusion Timing of adjuvant systemic therapy can influence OS in TNBC patients. Efforts should be made to avoid unnecessary delays in administering chemotherapy to ensure timely initiation of systemic therapy and optimize patient outcomes.
ISSN:15737217
01676806
DOI:10.1007/s10549-023-07207-4